Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Ew trends in the development of miRNA therapeutic strategies in oncology (Review)

International Journal of Oncology

Volumn 49, Issue 1, 2016, Pages 5-32

  Gambari, Roberto ^a   Brognara, Eleonora ^a   Spandidos, Demetrios A ^b   Fabbri, Enrica ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

AntagomiR; Epithelial mesenchymal transition; Metastasis; MicroRNAs; MiR124; MiRNA replacement therapy; Peptide nucleic acids

Indexed keywords

ANTAGOMIR; CETUXIMAB; CISPLATIN; MICRORNA; MICRORNA 1; MICRORNA 122; MICRORNA 124; MICRORNA 126; MICRORNA 128; MICRORNA 137; MICRORNA 148A; MICRORNA 148B; MICRORNA 149; MICRORNA 15A; MICRORNA 16; MICRORNA 181B; MICRORNA 18A; MICRORNA 204; MICRORNA 21; MICRORNA 221; MICRORNA 29B; MICRORNA 30B; MICRORNA 31; MICRORNA 33A; MICRORNA 33B; MICRORNA 34A; MICRORNA 34B; MICRORNA 9; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GENE THERAPY; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; DOWN REGULATION; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GLIOMA; GROWTH INHIBITION; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; METASTASIS; MITOCHONDRIAL REPLACEMENT THERAPY; NEUROBLASTOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA SEQUENCE; SKIN CARCINOMA; TUMOR INVASION; TUMOR SUPPRESSOR GENE; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; DRUG EFFECTS; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANTAGOMIRS; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84978431893     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3503     Document Type: Review

References (372)

1. Mazière P and Enright AJ: Prediction of microRNA targets. Drug Discov Today 12: 452-458, 2007.
2. Witkos TM, Koscianska E and Krzyzosiak WJ: Practical aspects of microRNA target prediction. Curr Mol Med 11: 93-109, 2011.
3. Ghelani HS, Rachchh MA and Gokani RH: MicroRNAs as newer therapeutic targets: A big hope from a tiny player. J Pharmacol Pharmacother 3: 217-227, 2012.
4. Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11: 597-610, 2010.
5. Sun K and Lai EC: Adult-specific functions of animal microRNAs. Nat Rev Genet 14: 535-548, 2013.
6. Chekulaeva M and Filipowicz W: Mechanisms of miRNAmediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol 21: 452-460, 2009.
7. Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840, 2010.
8. Cammaerts S, Strazisar M, De Rijk P and Del Favero J: Genetic variants in microRNA genes: Impact on microRNA expression, function, and disease. Front Genet 6: 186, 2015.
9. Friedländer MR, Lizano E, Houben AJS, Bezdan D, Báñez Coronel M, Kudla G, Mateu-Huertas E, Kagerbauer B, González J, Chen KC, et al: Evidence for the biogenesis of more than 1,000 novel human microRNAs. Genome Biol 15: R57, 2014.
10. Cheng WC, Chung IF, Tsai CF, Huang TS, Chen CY, Wang SC, Chang TY, Sun HJ, Chao JY, Cheng CC, et al: YM500v2: a small RNA sequencing (smRNA-seq) database for human cancer miRNome research. Nucleic Acids Res 43: D862-D867, 2015.
11. Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, et al: Analysis of 13 cell types reveals evidence for the expression of numerous novel primate-and tissue-specific microRNAs. Proc Natl Acad Sci USA 112: E1106-E1115, 2015.
12. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34: D140-D144, 2006.
13. Kozomara A and Griffiths-Jones S: miRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 42: D68-D73, 2014.
14. Taccioli C, Fabbri E, Visone R, Volinia S, Calin GA, Fong LY, Gambari R, Bottoni A, Acunzo M, Hagan J, et al: UCbase and miRfunc: A database of ultraconserved sequences and microRNA function. Nucleic Acids Res 37: D41-D48, 2009.
15. Witwer KW: Data submission and quality in microarray-based microRNA profiling. Clin Chem 59: 392-400, 2013.
16. Xie B, Ding Q, Han H and Wu D: miRCancer: A microRNAcancer association database constructed by text mining on literature. Bioinformatics 29: 638-644, 2013.
17. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773, 2005.
18. Peter ME: Targeting of mRNAs by multiple miRNAs: The next step. Oncogene 29: 2161-2164, 2010.
19. Bianchi N, Finotti A, Ferracin M, Lampronti I, Zuccato C, Breveglieri G, Brognara E, Fabbri E, Borgatti M, Negrini M, et al: Increase of microRNA-210, decrease of raptor gene expression and alteration of mammalian target of rapamycin regulated proteins following mithramycin treatment of human erythroid cells. PLoS One 10: e0121567, 2015.
20. Subramanian S and Steer CJ: MicroRNAs as gatekeepers of apoptosis. J Cell Physiol 223: 289-298, 2010.
21. Wang Y and Blelloch R: Cell cycle regulation by MicroRNAs in embryonic stem cells. Cancer Res 69: 4093-4096, 2009.
22. Fabbri E, Borgatti M, Montagner G, Bianchi N, Finotti A, Lampronti I, Bezzerri V, Dechecchi MC, Cabrini G and Gambari R: Expression of microRNA-93 and Interleukin-8 during Pseudomonas aeruginosa-mediated induction of proinflammatory responses. Am J Respir Cell Mol Biol 50: 1144-1155, 2014.
23. Faruq O and Vecchione A: microRNA: Diagnostic perspective. Front Med Lausanne 2: 51, 2015.
24. Shalaby T, Fiaschetti G, Baumgartner M and Grotzer MA: Significance and therapeutic value of miRNAs in embryonal neural tumors. Molecules 19: 5821-5862, 2014.
25. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004, 2004.
26. Palmero EI, de Campos SG, Campos M, de Souza NC, Guerreiro ID, Carvalho AL and Marques MM: Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet Mol Biol 34: 363-370, 2011.
27. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ and Wang K: The microRNA spectrum in 12 body fluids. Clin Chem 56: 1733-1741, 2010.
28. Fayyad-Kazan H, Bitar N, Najar M, Lewalle P, Fayyad-Kazan M, Badran R, Hamade E, Daher A, Hussein N, ElDirani R, et al: Circulating miR150 and miR342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med 11: 31, 2013.
29. Neviani P and Fabbri M: Exosomic microRNAs in the tumor microenvironment. Front Med Lausanne 2: 47, 2015.
30. Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, Welker MW, Elhendawy M, Zeuzem S, Piiper A, et al: Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 49: 3442-3449, 2013.
31. He Y, Lin J, Kong D, Huang M, Xu C, Kim TK, Etheridge A, Luo Y, Ding Y and Wang K: Current state of circulating MicroRNAs as cancer biomarkers. Clin Chem 61: 1138-1155, 2015.
32. Westphal M and Lamszus K: Circulating biomarkers for gliomas. Nat Rev Neurol 11: 556-566, 2015.
33. Yau TO, Wu CW, Dong Y, Tang CM, Ng SS, Chan FK, Sung JJ and Yu J: microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br J Cancer 111: 1765-1771, 2014.
34. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR and Zhang W: Circulating plasma MiR141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 6: e17745, 2011.
35. Czech MP: MicroRNAs as therapeutic targets. N Engl J Med 354: 1194-1195, 2006.
36. Brown BD and Naldini L: Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 10: 578-585, 2009.
37. Kota SK and Balasubramanian S: Cancer therapy via modulation of micro RNA levels: A promising future. Drug Discov Today 15: 733-740, 2010.
38. Small EM and Olson EN: Pervasive roles of microRNAs in cardiovascular biology. Nature 469: 336-342, 2011.
39. Bader AG and Lammers P: The Therapeutic Potential of microRNAs. Discovery Technology, 2011.
40. Rothschild SI: microRNA therapies in cancer. Mol Cell Ther 2: 7, 2014.
41. van Rooij E and Kauppinen S: Development of microRNA therapeutics is coming of age. EMBO Mol Med 6: 851-864, 2014.
42. Orellana EA and Kasinski AL: MicroRNAs in cancer: A historical perspective on the path from discovery to therapy. Cancers (Basel) 7: 1388-1405, 2015.
43. Berindan-Neagoe I, Monroig PC, Pasculli B and Calin GA: MicroRNAome genome: A treasure for cancer diagnosis and therapy. CA Cancer J Clin 64: 311-336, 2014.
44. Bernardo BC, Ooi JY, Lin RC and McMullen JR: miRNA therapeutics: A new class of drugs with potential therapeutic applications in the heart. Future Med Chem 7: 1771-1792, 2015.
45. Weiler J, Hunziker J and Hall J: Anti-miRNA oligonucleotides (AMOs): Ammunition to target miRNAs implicated in human disease? Gene Ther 13: 496-502, 2006.
46. Lu Y, Xiao J, Lin H, Bai Y, Luo X, Wang Z and Yang B: A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res 37: e24, 2009.
47. Lennox KA and Behlke MA: Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther 18: 1111-1120, 2011.
48. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, et al: Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43: 371-378, 2011.
49. Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjärn M, Hansen HF, Berger U, et al: LNA-mediated microRNA silencing in non-human primates. Nature 452: 896-899, 2008.
50. Stenvang J, Silahtaroglu AN, Lindow M, Elmen J and Kauppinen S: The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol 18: 89-102, 2008.
51. Chabot S, Teissié J and Golzio M: Targeted electro-delivery of oligonucleotides for RNA interference: siRNA and antimiR. Adv Drug Deliv Rev 81: 161-168, 2015.
52. Lundin KE, Højland T, Hansen BR, Persson R, Bramsen JB, Kjems J, Koch T, Wengel J and Smith CI: Biological activity and biotechnological aspects of locked nucleic acids. Adv Genet 82: 47-107, 2013.
53. Staedel C, Varon C, Nguyen PH, Vialet B, Chambonnier L, Rousseau B, Soubeyran I, Evrard S, Couillaud F and Darfeuille F: Inhibition of gastric tumor cell growth using seed-targeting LNA as specific, long-lasting MicroRNA inhibitors. Mol Ther Nucleic Acids 4: e246, 2015.
54. Avitabile C, Accardo A, Ringhieri P, Morelli G, Saviano M, Montagner G, Fabbri E, Gallerani E, Gambari R and Romanelli A: Incorporation of naked peptide nucleic acids into liposomes leads to fast and efficient delivery. Bioconjug Chem 26: 1533-1541, 2015.
55. Fabbri E, Manicardi A, Tedeschi T, Sforza S, Bianchi N, Brognara E, Finotti A, Breveglieri G, Borgatti M, Corradini R, et al: Modulation of the biological activity of microRNA-210 with peptide nucleic acids (PNAs). ChemMedChem 6: 2192-2202, 2011.
56. Brognara E, Fabbri E, Bazzoli E, Montagner G, Ghimenton C, Eccher A, Cantù C, Manicardi A, Bianchi N, Finotti A, et al: Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR221. J Neurooncol 118: 19-28, 2014.
57. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, et al: MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518: 107-110, 2015.
58. Morris JK, Chomyk A, Song P, Parker N, Deckard S, Trapp BD, Pimplikar SW and Dutta R: Decrease in levels of the evolutionarily conserved microRNA miR124 affects oligodendrocyte numbers in Zebrafish, Danio rerio. Invert Neurosci 15: 4, 2015.
59. Conte I, Hadfield KD, Barbato S, Carrella S, Pizzo M, Bhat RS, Carissimo A, Karali M, Porter LF, Urquhart J, et al: MiR204 is responsible for inherited retinal dystrophy associated with ocular coloboma. Proc Natl Acad Sci USA 112: E3236-E3245, 2015.
60. Ristori E, Lopez-Ramirez MA, Narayanan A, Hill-Teran G, Moro A, Calvo CF, Thomas JL and Nicoli S: A Dicer-miR107 interaction regulates biogenesis of specific miRNAs crucial for neurogenesis. Dev Cell 32: 546-560, 2015.
61. Ebert MS, Neilson JR and Sharp PA: MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4: 721-726, 2007.
62. Ebert MS and Sharp PA: MicroRNA sponges: Progress and possibilities. RNA 16: 2043-2050, 2010.
63. Kluiver J, Gibcus JH, Hettinga C, Adema A, Richter MK, Halsema N, Slezak-Prochazka I, Ding Y, Kroesen BJ and van den Berg A: Rapid generation of microRNA sponges for microRNA inhibition. PLoS One 7: e29275, 2012a.
64. Kluiver J, Slezak-Prochazka I, Smigielska-Czepiel K, Halsema N, Kroesen BJ and van den Berg A: Generation of miRNA sponge constructs. Methods 58: 113-117, 2012.
65. Li KC, Chang YH, Yeh CL and Hu YC: Healing of osteoporotic bone defects by baculovirus-engineered bone marrow-derived MSCs expressing MicroRNA sponges. Biomaterials 74: 155-166, 2016.
66. de Melo Maia B, Ling H, Monroig P, Ciccone M, Soares FA, Calin GA and Rocha RM: Design of a miRNA sponge for the miR17 miRNA family as a therapeutic strategy against vulvar carcinoma. Mol Cell Probes 29: 420-426, 2015.
67. Tay FC, Lim JK, Zhu H, Hin LC and Wang S: Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells. Adv Drug Deliv Rev 81: 117-127, 2015.
68. Liu Y, Han Y, Zhang H, Nie L, Jiang Z, Fa P, Gui Y and Cai Z: Synthetic miRNA-mowers targeting miR183-96-182 cluster or miR210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS One 7: e52280, 2012.
69. Choi WY, Giraldez AJ and Schier AF: Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR430. Science 318: 271-274, 2007.
70. Haraguchi T, Ozaki Y and Iba H: Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res 37: e43, 2009.
71. Krol J, Busskamp V, Markiewicz I, Stadler MB, Ribi S, Richter J, Duebel J, Bicker S, Fehling HJ, Schübeler D, et al: Characterizing light-regulated retinal microRNAs reveals rapid turnover as a common property of neuronal microRNAs. Cell 141: 618-631, 2010.
72. Cassidy JJ, Straughan AJ and Carthew RW: Differential masking of natural genetic variation by miR9a in Drosophila. Genetics 202: 675-687, 2016.
73. Wang Z: The principles of MiRNA-masking antisense oligonucleotides technology. Methods Mol Biol 676: 43-49, 2011.
74. Bak RO, Hollensen AK and Mikkelsen JG: Managing microRNAs with vector-encoded decoy-type inhibitors. Mol Ther 21: 1478-1485, 2013.
75. Murakami K and Miyagishi M: Tiny masking locked nucleic acids effectively bind to mRNA and inhibit binding of microRNAs in relation to thermodynamic stability. Biomed Rep 2: 509-512, 2014.
76. Shin KJ, Wall EA, Zavzavadjian JR, Santat LA, Liu J, Hwang JI, Rebres R, Roach T, Seaman W, Simon MI, et al: A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci USA 103: 13759-13764, 2006.
77. Askou AL, Aagaard L, Kostic C, Arsenijevic Y, Hollensen AK, Bek T, Jensen TG, Mikkelsen JG and Corydon TJ: Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA-and protein-based antiangiogenic factors. Mol Ther Methods Clin Dev 2: 14064, 2015.
78. Winbanks CE, Beyer C, Hagg A, Qian H, Sepulveda PV and Gregorevic P: miR206 represses hypertrophy of myogenic cells but not muscle fibers via inhibition of HDAC4. PLoS One 8: e73589, 2013.
79. Montgomery RL, Yu G, Latimer PA, Stack C, Robinson K, Dalby CM, Kaminski N and van Rooij E: MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol Med 6: 1347-1356, 2014.
80. Bader AG: miR34-a microRNA replacement therapy is headed to the clinic. Front Genet 3: 120, 2012.
81. Kwekkeboom RF, Lei Z, Doevendans PA, Musters RJ and Sluijter JP: Targeted delivery of miRNA therapeutics for cardiovascular diseases: Opportunities and challenges. Clin Sci (Lond) 127: 351-365, 2014.
82. Sherr CJ: Principles of tumor suppression. Cell 116: 235-246, 2004.
83. Lee YS and Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21: 1025-1030, 2007.
84. Mayr C, Hemann MT and Bartel DP: Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315: 1576-1579, 2007.
85. Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E and Peter ME: Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 6: 2585-2590, 2007.
86. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP and Krueger LJ: MicroRNA let-7a downregulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67: 9762-9770, 2007.
87. Müller DW and Bosserhoff AK: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 27: 6698-6706, 2008.
88. Peng Y, Laser J, Shi G, Mittal K, Melamed J, Lee P and Wei JJ: Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res 6: 663-673, 2008.
89. Bader AG, Brown D and Winkler M: The promise of microRNA replacement therapy. Cancer Res 70: 7027-7030, 2010.
90. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D and Bader AG: Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70: 5923-5930, 2010.
91. Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK and Aigner A: MicroRNA replacement therapy for miR145 and miR33a is efficacious in a model of colon carcinoma. Cancer Res 71: 5214-5224, 2011.
92. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG and Slack FJ: Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19: 1116-1122, 2011.
93. Buechner J, Tømte E, Haug BH, Henriksen JR, Løkke C, Flægstad T and Einvik C: Tumour-suppressor microRNAs let-7 and miR101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer 105: 296-303, 2011.
94. Scheibner KA, Teaboldt B, Hauer MC, Chen X, Cherukuri S, Guo Y, Kelley SM, Liu Z, Baer MR, Heimfeld S, et al: MiR27a functions as a tumor suppressor in acute leukemia by regulating 14-3-3?. PLoS One 7: e50895, 2012.
95. Thomas M, Lange-Grünweller K, Weirauch U, Gutsch D, Aigner A, Grünweller A and Hartmann RK: The proto-oncogene Pim-1 is a target of miR33a. Oncogene 31: 918-928, 2012.
96. Endo H, Muramatsu T, Furuta M, Uzawa N, Pimkhaokham A, Amagasa T, Inazawa J and Kozaki K: Potential of tumorsuppressive miR596 targeting LGALS3BP as a therapeutic agent in oral cancer. Carcinogenesis 34: 560-569, 2013.
97. Wu Y, Crawford M, Mao Y, Lee RJ, Davis IC, Elton TS, Lee LJ and Nana-Sinkam SP: Therapeutic delivery of microRNA29b by cationic lipoplexes for lung cancer. Mol Ther Nucleic Acids 2: e84, 2013.
98. Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, et al: Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: A novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res 19: 2355-2367, 2013.
99. Liang Z, Ahn J, Guo D, Votaw JR and Shim H: MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm Res 30: 1008-1016, 2013.
100. Møller HG, Rasmussen AP, Andersen HH, Johnsen KB, Henriksen M and Duroux M: A systematic review of microRNA in glioblastoma multiforme: Micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol 47: 131-144, 2013.
101. Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O and Granot G: Restoration of miR424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment. Cancer Lett 360: 245-256, 2015.
102. Lee YM, Lee JY, Ho CC, Hong QS, Yu SL, Tzeng CR, Yang PC and Chen HW: miRNA-34b as a tumor suppressor in estrogendependent growth of breast cancer cells. Breast Cancer Res 13: R116, 2011.
103. Huang P, Ye B, Yang Y, Shi J and Zhao H: MicroRNA-181 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2. Tumour Biol 36: 3381-3387, 2015.
104. Su R, Lin HS, Zhang XH, Yin XL, Ning HM, Liu B, Zhai PF, Gong JN, Shen C, Song L, et al: MiR181 family: Regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets. Oncogene 34: 3226-3239, 2015.
105. Bachetti T, Di Zanni E, Ravazzolo R and Ceccherini I: miR204 mediates post-transcriptional down-regulation of PHOX2B gene expression in neuroblastoma cells. Biochim Biophys Acta 1849: 1057-1065, 2015.
106. Fernandez S, Risolino M, Mandia N, Talotta F, Soini Y, Incoronato M, Condorelli G, Banfi S and Verde P: miR340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene 34: 3240-3250, 2015.
107. Liu G, Liu Y, Yang Z, Wang J, Li D and Zhang X: Tumor suppressor microRNA-18a regulates tumor proliferation and invasion by targeting TBPL1 in colorectal cancer cells. Mol Med Rep 12: 7643-7648, 2015.
108. Xishan Z, Ziying L, Jing D and Gang L: MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia. Sci Rep 5: 12460, 2015.
109. Zhao Z, Ma X, Sung D, Li M, Kosti A, Lin G, Chen Y, Pertsemlidis A, Hsiao TH and Du L: microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest. RNA Biol 12: 538-554, 2015.
110. Kalinowski FC, Brown RA, Ganda C, Giles KM, Epis MR, Horsham J and Leedman PJ: microRNA-7: A tumor suppressor miRNA with therapeutic potential. Int J Biochem Cell Biol 54: 312-317, 2014.
111. Gu DN, Huang Q and Tian L: The molecular mechanisms and therapeutic potential of microRNA-7 in cancer. Expert Opin Ther Targets 19: 415-426, 2015.
112. Nohata N, Hanazawa T, Enokida H and Seki N: microRNA1/133a and microRNA-206/133b clusters: Dysregulation and functional roles in human cancers. Oncotarget 3: 9-21, 2012.
113. Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, et al: MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res 40: 3689-3703, 2012.
114. Chang YS, Chen WY, Yin JJ, Sheppard-Tillman H, Huang J and Liu YN: EGF receptor pomotes prostate cancer bone metastasis by downregulating miR1 and activating TWIST1. Cancer Res 75: 3077-3086, 2015.
115. Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, Jiang L, Zhang Y and Dou J: MiR7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells 32: 2858-2868, 2014a.
116. Okuda H, Xing F, Pandey PR, Sharma S, Watabe M, Pai SK, Mo YY, Iiizumi-Gairani M, Hirota S, Liu Y, et al: miR7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res 73: 1434-1444, 2013.
117. Zhou X, Hu Y, Dai L, Wang Y, Zhou J, Wang W, Di W and Qiu L: MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer. PLoS One 9: e96718, 2014.
118. Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ and Rosner MR: Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J 28: 347-358, 2009.
119. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756, 2004.
120. Shi XB, Tepper CG and deVere White RW: Cancerous miRNAs and their regulation. Cell Cycle 7: 1529-1538, 2008.
121. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack FJ: RAS is regulated by the let-7 microRNA family. Cell 120: 635-647, 2005.
122. Zheng L, Qi T, Yang D, Qi M, Li D, Xiang X, Huang K and Tong Q: microRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1. PLoS One 8: e55719, 2013.
123. Aqeilan RI, Calin GA and Croce CM: miR15a and miR16-1 in cancer: Discovery, function and future perspectives. Cell Death Differ 17: 215-220, 2010.
124. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529, 2002.
125. Pekarsky Y and Croce CM: Role of miR15/16 in CLL. Cell Death Differ 22: 6-11, 2015.
126. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, et al: The miR15a-miR16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271-1277, 2008.
127. Kang W, Tong JH, Lung RW, Dong Y, Zhao J, Liang Q, Zhang L, Pan Y, Yang W, Pang JC, et al: Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma. Mol Cancer 14: 52, 2015.
128. Chen F, Chen L, He H, Huang W, Zhang R, Li P, et al: Up-regulation of microRNA-16 in glioblastoma inhibits the function of endothelial cells and tumor angiogenesis by targeting Bmi-1. Anticancer Agents Med Chem, 2015.
129. Humphreys KJ, McKinnon RA and Michael MZ: miR18a inhibits CDC42 and plays a tumour suppressor role in colorectal cancer cells. PLoS One 9: e112288, 2014.
130. Zoni E, van der Horst G, van de Merbel AF, Chen L, Rane JK, Pelger RC, Collins AT, Visakorpi T, Snaar-Jagalska BE, Maitland NJ, et al: miR25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of v-and 6 integrin expression. Cancer Res 75: 2326-2336, 2015.
131. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, Chen CJ, Hildesheim A, Sugden B and Ahlquist P: MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 105: 5874-5878, 2008.
132. Ugalde AP, Ramsay AJ, de la Rosa J, Varela I, Mariño G, Cadiñanos J, Lu J, Freije JM and López-Otín C: Aging and chronic DNA damage response activate a regulatory pathway involving miR29 and p53. EMBO J 30: 2219-2232, 2011.
133. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, et al: MicroRNA 29b functions in acute myeloid leukemia. Blood 114: 5331-5341, 2009a.
134. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, et al: MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113: 6411-6418, 2009b.
135. Kapinas K, Kessler CB and Delany AM: miR29 suppression of osteonectin in osteoblasts: Regulation during differentiation and by canonical Wnt signaling. J Cell Biochem 108: 216-224, 2009.
136. Mott JL, Kobayashi S, Bronk SF and Gores GJ: miR29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26: 6133-6140, 2007.
137. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, et al: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104: 15805-15810, 2007.
138. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH and Zhuang SM: Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 51: 836-845, 2010.
139. Filkowski JN, Ilnytskyy Y, Tamminga J, Koturbash I, Golubov A, Bagnyukova T, Pogribny IP and Kovalchuk O: Hypomethylation and genome instability in the germline of exposed parents and their progeny is associated with altered miRNA expression. Carcinogenesis 31: 1110-1115, 2010.
140. Wang Y, Zhang X, Li H, Yu J and Ren X: The role of miRNA-29 family in cancer. Eur J Cell Biol 92: 123-128, 2013.
141. Hu W, Dooley J, Chung SS, Chandramohan D, Cimmino L, Mukherjee S, Mason CE, de Strooper B, Liston A and Park CY: miR29a maintains mouse hematopoietic stem cell self-renewal by regulating Dnmt3a. Blood 125: 2206-2216, 2015.
142. Li L and Wang B: Overexpression of microRNA-30b improves adenovirus-mediated p53 cancer gene therapy for laryngeal carcinoma. Int J Mol Sci 15: 19729-19740, 2014.
143. Hou C, Sun B, Jiang Y, Zheng J, Yang N, Ji C, Liang Z, Shi J, Zhang R, Liu Y, et al: MicroRNA-31 inhibits lung adenocarcinoma stem-like cells via down-regulation of MET-PI3K-Akt signaling pathway. Anticancer Agents Med Chem 16: 501-518, 2016.
144. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL and Weinberg RA: A pleiotropically acting microRNA, miR31, inhibits breast cancer metastasis. Cell 137: 1032-1046, 2009.
145. Sossey-Alaoui K, Downs-Kelly E, Das M, Izem L, Tubbs R and Plow EF: WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR31, during the invasion-metastasis cascade. Int J Cancer 129: 1331-1343, 2011.
146. Lin Y, Liu AY, Fan C, Zheng H, Li Y, Zhang C, Wu S, Yu D, Huang Z, Liu F, et al: MicroRNA-33b inhibits breast cancer metastasis by targeting HMGA2, SALL4 and Twist1. Sci Rep 5: 9995, 2015.
147. Xu N, Li Z, Yu Z, Yan F, Liu Y, Lu X and Yang W: MicroRNA-33b suppresses migration and invasion by targeting c-Myc in osteosarcoma cells. PLoS One 9: e115300, 2014.
148. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134, 2007.
149. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al: p53-mediated activation of miRNA34 candidate tumorsuppressor genes. Curr Biol 17: 1298-1307, 2007.
150. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, Deguchi T and Ito M: Effects of miR34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377: 114-119, 2008.
151. Leucci E, Cocco M, Onnis A, De Falco G, van Cleef P, Bellan C, van Rijk A, Nyagol J, Byakika B, Lazzi S, et al: MYC translocation-negative classical Burkitt lymphoma cases: An alternative pathogenetic mechanism involving miRNA deregulation. J Pathol 216: 440-450, 2008.
152. Saito Y, Nakaoka T and Saito H: microRNA-34a as a therapeutic agent against human cancer. J Clin Med 4: 1951-1959, 2015.
153. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, Zhang Q, Thiele CJ, Slack A, Shohet J, et al: The MYCN oncogene is a direct target of miR34a. Oncogene 27: 5204-5213, 2008.
154. Yamakuchi M, Ferlito M and Lowenstein CJ: miR34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 105: 13421-13426, 2008.
155. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Körner H, Knyazev P, Diebold J and Hermeking H: Inactivation of miR34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7: 2591-2600, 2008.
156. Yang S, Li Y, Gao J, Zhang T, Li S, Luo A, Chen H, Ding F, Wang X and Liu Z: MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene 32: 4294-4303, 2013.
157. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, Deng Y, Zhao J, Jiang S, Yuan Y, et al: TGF-miR34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 22: 291-303, 2012.
158. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al: The microRNA miR34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211-215, 2011.
159. Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, et al: miR34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 512: 431-435, 2014.
160. Wang LG, Ni Y, Su BH, Mu XR, Shen HC and Du JJ: MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met. Int J Oncol 42: 957-962, 2013.
161. Yu Z, Kim J, He L, Creighton CJ, Gunaratne PH, Hawkins SM and Matzuk MM: Functional analysis of miR34c as a putative tumor suppressor in high-grade serous ovarian cancer. Biol Reprod 91: 113, 2014.
162. Liu XY, Liu ZJ, He H, Zhang C and Wang YL: MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1. Am J Cancer Res 5: 3015-3029, 2015.
163. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, et al: MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 122: 2884-2897, 2012.
164. Taniguchi K, Sugito N, Kumazaki M, Shinohara H, Yamada N, Nakagawa Y, Ito Y, Otsuki Y, Uno B, Uchiyama K, et al: MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/ PKM2 feedback cascade in colorectal cancer. Cancer Lett 363: 17-27, 2015.
165. Huang TC, Chang HY, Chen CY, Wu PY, Lee H, Liao YF, Hsu WM, Huang HC and Juan HF: Silencing of miR124 induces neuroblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR. FEBS Lett 585: 3582-3586, 2011.
166. Kato T, Enomoto A, Watanabe T, Haga H, Ishida S, Kondo Y, Furukawa K, Urano T, Mii S, Weng L, et al: TRIM27/MRTF-Bdependent integrin 1 expression defines leading cells in cancer cell collectives. Cell Rep 7: 1156-1167, 2014.
167. Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 61: 278-289, 2012.
168. Wang X, Wu Q, Xu B, Wang P, Fan W, Cai Y, Gu X and Meng F: miR124 exerts tumor suppressive functions on the cell proliferation, motility and angiogenesis of bladder cancer by fine-tuning UHRF1. FEBS J 282: 4376-4388, 2015.
169. Zhang C, Hu Y, Wan J and He H: MicroRNA-124 suppresses the migration and invasion of osteosarcoma cells via targeting ROR2-mediated non-canonical Wnt signaling. Oncol Rep 34: 2195-2201, 2015.
170. Sun Y, Ai X, Shen S and Lu S: NF-B-mediated miR124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10. Oncotarget 6: 8244-8254, 2015a.
171. Sun Y, Luo ZM, Guo XM, Su DF and Liu X: An updated role of microRNA-124 in central nervous system disorders: A review. Front Cell Neurosci 9: 193, 2015b.
172. Chen Z, Liu S, Tian L, Wu M, Ai F, Tang W, Zhao L, Ding J, Zhang L and Tang A: miR124 and miR506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1. Oncotarget 6: 38139-38150, 2015.
173. Zhang Y, Li H, Han J and Zhang Y: Down-regulation of microRNA-124 is correlated with tumor metastasis and poor prognosis in patients with lung cancer. Int J Clin Exp Pathol 8: 1967-1972, 2015.
174. Cowden Dahl KD, Dahl R, Kruichak JN, Hudson LG: The epidermal growth factor receptor responsive miR125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 11: 1208-1215, 2009.
175. Fan Z, Cui H, Xu X, Lin Z, Zhang X, Kang L, Han B, Meng J, Yan Z, Yan X, et al: MiR125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3. Oncotarget 6: 25266-25280, 2015.
176. Sun Y, Bai Y, Zhang F, Wang Y, Guo Y and Guo L: miR126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun 391: 1483-1489, 2010.
177. Xiong Y, Kotian S, Zeiger MA, Zhang L and Kebebew E: miR126-3p inhibits thyroid cancer cell growth and metastasis, and is associated with aggressive thyroid cancer. PLoS One 10: e0130496, 2015.
178. Wang CZ, Yuan P and Li Y: MiR126 regulated breast cancer cell invasion by targeting ADAM9. Int J Clin Exp Pathol 8: 6547-6553, 2015.
179. Wen Q, Zhao J, Bai L, Wang T, Zhang H and Ma Q: miR126 inhibits papillary thyroid carcinoma growth by targeting LRP6. Oncol Rep 34: 2202-2210, 2015.
180. Jiang L, He A, Zhang Q and Tao C: miR126 inhibits cell growth, invasion, and migration of osteosarcoma cells by downregulating ADAM-9. Tumour Biol 35: 12645-12654, 2014.
181. Du C, Lv Z, Cao L, Ding C, Gyabaah OA, Xie H, Zhou L, Wu J and Zheng S: MiR126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2. J Transl Med 12: 259, 2014.
182. Zhang Y, Wang X, Xu B, Wang B, Wang Z, Liang Y, Zhou J, Hu J and Jiang B: Epigenetic silencing of miR126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep 30: 1976-1984, 2013.
183. Png KJ, Halberg N, Yoshida M and Tavazoie SF: A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481: 190-194, 2011.
184. Shi ZM, Wang J, Yan Z, You YP, Li CY, Qian X, Yin Y, Zhao P, Wang YY, Wang XF, et al: MiR128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS One 7: e32709, 2012.
185. Wuchty S, Arjona D, Li A, Kotliarov Y, Walling J, Ahn S, Zhang A, Maric D, Anolik R, Zenklusen JC, et al: Prediction of associations between microRNAs and gene expression in glioma biology. PLoS One 6: e14681, 2011.
186. Zhang Y, Chao T, Li R, Liu W, Chen Y, Yan X, Gong Y, Yin B, Liu W, Qiang B, et al: MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J Mol Med Berl 87: 43-51, 2009.
187. Huang CY, Huang XP, Zhu JY, Chen ZG, Li XJ, Zhang XH, Huang S, He JB, Lian F, Zhao YN, et al: miR128-3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients. Oncol Rep 33: 2889-2898, 2015.
188. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and Matsubara H: miR145, miR133a and miR133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127: 2804-2814, 2010.
189. Kroiss A, Vincent S, Decaussin-Petrucci M, Meugnier E, Viallet J, Ruffion A, Chalmel F, Samarut J and Allioli N: Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene 34: 2846-2855, 2015.
190. Liang L, Li X, Zhang X, Lv Z, He G, Zhao W, Ren X, Li Y, Bian X, Liao W, et al: MicroRNA-137, an HMGA1 target, suppresses colorectal cancer cell invasion and metastasis in mice by directly targeting FMNL2. Gastroenterology 144: 624-635.e4, 2013.
191. Xia H, Sun S, Wang B, Wang T, Liang C, Li G, Huang C, Qi D and Chu X: miR143 inhibits NSCLC cell growth and metastasis by targeting Limk1. Int J Mol Sci 15: 11973-11983, 2014.
192. Gao P, Xing AY, Zhou GY, Zhang TG, Zhang JP, Gao C, Li H and Shi DB: The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene 32: 491-501, 2013.
193. Zhang H, Pu J, Qi T, Qi M, Yang C, Li S, Huang K, Zheng L and Tong Q: MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha. Oncogene 33: 387-397, 2014.
194. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J and Benz CC: Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27: 5643-5647, 2008.
195. Lin SL, Chiang A, Chang D and Ying SY: Loss of miR146a function in hormone-refractory prostate cancer. RNA 14: 417-424, 2008.
196. Zhang JP, Zeng C, Xu L, Gong J, Fang JH and Zhuang SM: MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Oncogene 33: 4069-4076, 2014.
197. Cimino D, De Pittà C, Orso F, Zampini M, Casara S, Penna E, Quaglino E, Forni M, Damasco C, Pinatel E, et al: miR148b is a major coordinator of breast cancer progression in a relapseassociated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. FASEB J 27: 1223-1235, 2013.
198. Bischoff A, Huck B, Keller B, Strotbek M, Schmid S, Boerries M, Busch H, Müller D and Olayioye MA: miR149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion. Cancer Res 74: 5256-5265, 2014.
199. Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, Volinia S, Taccioli C, Kipps TJ and Croce CM: miR181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 118: 3072-3079, 2011.
200. Kouri FM, Hurley LA, Daniel WL, Day ES, Hua Y, Hao L, Peng CY, Merkel TJ, Queisser MA, Ritner C, et al: miR182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes Dev 29: 732-745, 2015.
201. Leivonen SK, Rokka A, Ostling P, Kohonen P, Corthals GL, Kallioniemi O and Perälä M: Identification of miR193b targets in breast cancer cells and systems biological analysis of their functional impact. Mol Cell Proteomics 10: M110.005322, 2011.
202. Yang H, Liu P, Zhang J, Peng X, Lu Z, Yu S, Meng Y, Tong WM and Chen J: Long noncoding RNA MIR31HG exhibits oncogenic property in pancreatic ductal adenocarcinoma and is negatively regulated by miR193b. Oncogene: Nov 9, 2015 (Epub ahead of print).
203. Tan S, Li R, Ding K, Lobie PE and Zhu T: miR198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett 585: 2229-2234, 2011.
204. Bao W, Wang HH, Tian FJ, He XY, Qiu MT, Wang JY, Zhang HJ, Wang LH and Wan XP: A TrkB-STAT3-miR204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol Cancer 12: 155, 2013.
205. Xia Z, Liu F, Zhang J and Liu L: Decreased expression of MiRNA-204-5p contributes to glioma progression and promotes glioma cell growth, migration and invasion. PLoS One 10: e0132399, 2015.
206. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, et al: miR205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 69: 2287-2295, 2009.
207. Chen QY, Jiao DM, Yan L, Wu YQ, Hu HZ, Song J, Yan J, Wu LJ, Xu LQ and Shi JG: Comprehensive gene and microRNA expression profiling reveals miR206 inhibits MET in lung cancer metastasis. Mol Biosyst 11: 2290-2302, 2015.
208. Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, et al: Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 60: 598-609, 2014.
209. Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, et al: MiR218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 6: e1000879, 2010.
210. Wei JJ, Wu X, Peng Y, Shi G, Basturk O, Yang X, Daniels G, Osman I, Ouyang J, Hernando E, et al: Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res 17: 1297-1305, 2011.
211. Wang L, Yao J, Shi X, Hu L, Li Z, Song T and Huang C: MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC Cancer 13: 448, 2013.
212. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL and Massagué J: Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147-152, 2008.
213. Hurst DR, Edmonds MD and Welch DR: Metastamir: The field of metastasis-regulatory microRNA is spreading. Cancer Res 69: 7495-7498, 2009.
214. Li KK, Pang JC, Lau KM, Zhou L, Mao Y, Wang Y, Poon WS and Ng HK: MiR383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol 23: 413-425, 2013.
215. Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A, Krogh A, Bardram L, Hother C, Grønbæk K, Federspiel B, Lund AH and Friis-Hansen L: miR449 inhibits cell proliferation and is downregulated in gastric cancer. Mol Cancer 10: 29, 2011.
216. Luo W, Huang B, Li Z, Li H, Sun L, Zhang Q, Qiu X and Wang E: MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One 8: e64759, 2013.
217. Okamoto K, Ishiguro T, Midorikawa Y, Ohata H, Izumiya M, Tsuchiya N, Sato A, Sakai H and Nakagama H: miR493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in liver. EMBO J 31: 1752-1763, 2012.
218. Gu Y, Cheng Y, Song Y, Zhang Z, Deng M, Wang C, Zheng G and He Z: MicroRNA-493 suppresses tumor growth, invasion and metastasis of lung cancer by regulating E2F1. PLoS One 9: e102602, 2014.
219. Sakai H1, Sato A, Aihara Y, Ikarashi Y, Midorikawa Y, Kracht M, Nakagama H and Okamoto K: MKK 7 mediates miR493-dependent suppression of liver metastasis of colon cancer cells. Cancer Sci 105: 425-430, 2014.
220. Kikkawa N, Kinoshita T, Nohata N, Hanazawa T, Yamamoto N, Fukumoto I, Chiyomaru T, Enokida H, Nakagawa M, Okamoto Y, et al: microRNA-504 inhibits cancer cell proliferation via targeting CDK6 in hypopharyngeal squamous cell carcinoma. Int J Oncol 44: 2085-2092, 2014.
221. Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Gückel B, Fehm T, Schneeweiss A, et al: MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-B and TGF-signaling pathways. Oncogene 31: 4150-4163, 2012.
222. Song B, Ji W, Guo S, Liu A, Jing W, Shao C, Li G and Jin G: miR545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I. FEBS Lett 588: 4375-4381, 2014.
223. Bowen D, Zhe W, Xin Z, Shipeng F, Guoxin W, Jianxing H and Zhang B: MicroRNA-545 suppresses cell proliferation by targeting cyclin D1 and CDK4 in lung cancer cells. PLoS 9: 88022, 2014.
224. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801, 2005.
225. Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
226. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
227. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al: MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707, 2007.
228. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135, 2007.
229. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658, 2007.
230. Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282: 14328-14336, 2007.
231. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A and Lund AH: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR21 in breast cancer cells. J Biol Chem 283: 1026-1033, 2008.
232. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, et al: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111: 3183-3189, 2008.
233. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
234. White NM, Fatoohi E, Metias M, Jung K, Stephan C and Yousef GM: Metastamirs: A stepping stone towards improved cancer management. Nat Rev Clin Oncol 8: 75-84, 2011.
235. Zhou L, Liu F, Wang X and Ouyang G: The roles of microRNAs in the regulation of tumor metastasis. Cell Biosci 5: 32, 2015.
236. Wang XH, Cai P, Wang MH and Wang Z: microRNA 25 promotes osteosarcoma cell proliferation by targeting the cell cycle inhibitor p27. Mol Med Rep 10: 855-859, 2014.
237. Siu MK, Tsai YC, Chang YS, Yin JJ, Suau F, Chen WY and Liu YN: Transforming growth factor-promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway. Oncogene 34: 4767-4776, 2015.
238. Xia X, Li Y, Wang W, Tang F, Tan J, Sun L, Li Q, Sun L, Tang B and He S: MicroRNA-1908 functions as a glioblastoma oncogene by suppressing PTEN tumor suppressor pathway. Mol Cancer 14: 154, 2015.
239. Sachdeva M, Mito JK, Lee CL, Zhang M, Li Z, Dodd RD, Cason D, Luo L, Ma Y, Van Mater D, et al: MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. J Clin Invest 124: 4305-4319, 2014.
240. Tian Y, Luo A, Cai Y, Su Q, Ding F, Chen H and Liu Z: MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem 285: 7986-7994, 2010.
241. Wang YY, Ye ZY, Zhao ZS, Li L, Wang YX, Tao HQ, Wang HJ and He XJ: Clinicopathologic significance of miR10b expression in gastric carcinoma. Hum Pathol 44: 1278-1285, 2013.
242. Chan JA, Krichevsky AM and Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033, 2005.
243. Liu W, Zabirnyk O, Wang H, Shiao YH, Nickerson ML, Khalil S, Anderson LM, Perantoni AO and Phang JM: miR23b targets proline oxidase, a novel tumor suppressor protein in renal cancer. Oncogene 29: 4914-4924, 2010.
244. Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS and Bevan CL: Androgen-regulated processing of the oncomir miR27a, which targets Prohibitin in prostate cancer. Hum Mol Genet 21: 3112-3127, 2012.
245. Ng WL, Yan D, Zhang X, Mo YY and Wang Y: Over-expression of miR100 is responsible for the low-expression of ATM in the human glioma cell line: M059J. DNA Repair (Amst) 9: 1170-1175, 2010.
246. Zheng YS, Zhang H, Zhang XJ, Feng DD, Luo XQ, Zeng CW, Lin KY, Zhou H, Qu LH, Zhang P, et al: MiR100 regulates cell differentiation and survival by targeting RBSP3, a phosphataselike tumor suppressor in acute myeloid leukemia. Oncogene 31: 80-92, 2012.
247. Knackmuss U, Lindner SE, Aneichyk T, Kotkamp B, Knust Z, Villunger A and Herzog S: MAP3K11 is a tumor suppressor targeted by the oncomiR miR125b in early B cells. Cell Death Differ 23: 242-252, 2016.
248. Park JK, Henry JC, Jiang J, Esau C, Gusev Y, Lerner MR, Postier RG, Brackett DJ and Schmittgen TD: miR132 and miR212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun 406: 518-523, 2011.
249. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D and Cheng JQ: MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 285: 17869-17879, 2010.
250. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF and Wang ED: MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 70: 3119-3127, 2010.
251. Czyzyk-Krzeska MF and Zhang X: MiR155 at the heart of oncogenic pathways. Oncogene 33: 677-678, 2014.
252. Wang J and Wu J: Role of miR155 in breast cancer. Front Biosci (Landmark Ed) 17: 2350-2355, 2012.
253. Ling N, Gu J, Lei Z, Li M, Zhao J, Zhang HT and Li X: microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma. Oncol Rep 30: 2111-2118, 2013.
254. Musilova K and Mraz M: MicroRNAs in B-cell lymphomas: How a complex biology gets more complex. Leukemia 29: 1004-1017, 2015.
255. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, Boldrini R, Donfrancesco A, Federici V, Giacomini P, et al: AntagomiR17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 3: e2236, 2008.
256. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, et al: Aberrant miR182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 106: 1814-1819, 2009.
257. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al: MicroRNA expression profiling in human ovarian cancer: miR214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433, 2008.
258. Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han L, Jia ZF, Yang WD, Wang GX, Jiang T, You YP, et al: MiR221 and miR222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 9: 229, 2010.
259. Garofalo M, Quintavalle C, Romano G, Croce CM and Condorelli G: miR221/222 in cancer: Their role in tumor progression and response to therapy. Curr Mol Med 12: 27-33, 2012.
260. Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, del Basso De Caro M, Martinez-Montero JC, Incoronato M, Nuovo G, Croce CM, et al: miR221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP?. Oncogene 31: 858-868, 2012.
261. Chen WX, Hu Q, Qiu MT, Zhong SL, Xu JJ, Tang JH and Zhao JH: miR221/222: Promising biomarkers for breast cancer. Tumour Biol 34: 1361-1370, 2013.
262. Matsuzaki J and Suzuki H: Role of MicroRNAs-221/222 in digestive systems. J Clin Med 4: 1566-1577, 2015.
263. Würdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, Weissleder R, Breakefield XO and Krichevsky AM: miR296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 14: 382-393, 2008.
264. Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N, et al: MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res 71: 2926-2937, 2011.
265. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, et al: A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Adv Exp Med Biol 604: 17-46, 2007.
266. Xu Y, Jin J, Liu Y, Huang Z, Deng Y, You T, Zhou T, Si J and Zhuo W: Snail-regulated MiR375 inhibits migration and invasion of gastric cancer cells by targeting JAK2. PLoS One 9: e99516, 2014.
267. Lee DY, Deng Z, Wang CH and Yang BB: MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA 104: 20350-20355, 2007.
268. Tu K, Liu Z, Yao B, Han S and Yang W: MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma. Int J Oncol 48: 965-974, 2016.
269. Shao J, Cao J, Liu Y, Mei H, Zhang Y and Xu W: MicroRNA-519a promotes proliferation and inhibits apoptosis of hepatocellular carcinoma cells by targeting FOXF2. FEBS Open Bio 5: 893-899, 2015.
270. Ward A, Shukla K, Balwierz A, Soons Z, König R, Sahin O and Wiemann S: MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumoursuppressor genes in ER+ breast cancer. J Pathol 233: 368-379, 2014.
271. Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ and Kwok TT: Oncofetal H19-derived miR675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 31: 350-358, 2010.
272. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, TeruyaFeldstein J, Reinhardt F, Onder TT, Valastyan S, et al: miR9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256, 2010.
273. Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC, et al: LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med 18: 1511-1517, 2012.
274. White RA, Neiman JM, Reddi A, Han G, Birlea S, Mitra D, Dionne L, Fernandez P, Murao K, Bian L, et al: Epithelial stem cell mutations that promote squamous cell carcinoma metastasis. J Clin Invest 123: 4390-4404, 2013.
275. Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682-688, 2007.
276. Lin J, Teo S, Lam DH, Jeyaseelan K and Wang S: MicroRNA-10b pleiotropically regulates invasion, angiogenicity and apoptosis of tumor cells resembling mesenchymal subtype of glioblastoma multiforme. Cell Death Dis 3: e398, 2012.
277. Zhang WL, Zhang JH, Wu XZ, Yan T and Lv W: miR15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer. Int J Oncol 47: 1043-1053, 2015.
278. Wu Q, Yang Z, An Y, Hu H, Yin J, Zhang P, Nie Y, Wu K, Shi Y and Fan D: MiR19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell Death Dis 5: e1144, 2014.
279. Chang Y, Liu C, Yang J, Liu G, Feng F, Tang J, Hu L, Li L, Jiang F, Chen C, et al: MiR20a triggers metastasis of gallbladder carcinoma. J Hepatol 59: 518-527, 2013.
280. Zhao S, Yao D, Chen J, Ding N and Ren F: MiR20a promotes cervical cancer proliferation and metastasis in vitro and in vivo. PLoS One 10: e0120905, 2015.
281. Dean ZS, Riahi R and Wong PK: Spatiotemporal dynamics of microRNA during epithelial collective cell migration. Biomaterials 37: 156-163, 2015.
282. Peacock O, Lee AC, Cameron F, Tarbox R, Vafadar-Isfahani N, Tufarelli C and Lund JN: Inflammation and MiR21 pathways functionally interact to downregulate PDCD4 in colorectal cancer. PLoS One 9: e110267, 2014.
283. Xu J, Zhang W, Lv Q and Zhu D: Overexpression of miR21 promotes the proliferation and migration of cervical cancer cells via the inhibition of PTEN. Oncol Rep 33: 3108-3116, 2015.
284. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27: 2128-2136, 2008.
285. Melnik BC: MiR21: An environmental driver of malignant melanoma? J Transl Med 13: 202, 2015.
286. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor ST, Chin AR, et al: Cancer-secreted miR105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25: 501-515, 2014.
287. Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J, Chow A, O'Connor ST, Li S, Chin AR, et al: Breastcancer-secreted miR122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol 17: 183-194, 2015.
288. Lin CW, Chang YL, Chang YC, Lin JC, Chen CC, Pan SH, Wu CT, Chen HY, Yang SC, Hong TM, et al: MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun 4: 1877, 2013.
289. Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D and Schiemann WP: TGF-upregulates miR181a expression to promote breast cancer metastasis. J Clin Invest 123: 150-163, 2013.
290. Qiu Y, Luo X, Kan T, Zhang Y, Yu W, Wei Y, Shen N, Yi B and Jiang X: TGF-upregulates miR182 expression to promote gallbladder cancer metastasis by targeting CADM1. Mol Biosyst 10: 679-685, 2014.
291. Ren LH, Chen WX, Li S, He XY, Zhang ZM, Li M, Cao RS, Hao B, Zhang HJ, Qiu HQ, et al: MicroRNA-183 promotes proliferation and invasion in oesophageal squamous cell carcinoma by targeting programmed cell death 4. Br J Cancer 111: 2003-2013, 2014.
292. Korpal M, Lee ES, Hu G and Kang Y: The miR200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283: 14910-14914, 2008.
293. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, et al: Direct targeting of Sec23a by miR200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 17: 1101-1108, 2011.
294. Park SM, Gaur AB, Lengyel E and Peter ME: The miR200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22: 894-907, 2008.
295. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ: The miR200 family and miR205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601, 2008.
296. Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De Pittà C, et al: microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 30: 1990-2007, 2011.
297. Penna E, Orso F, Cimino D, Vercellino I, Grassi E, Quaglino E, Turco E and Taverna D: miR214 coordinates melanoma progression by upregulating ALCAM through TFAP2 and miR148b downmodulation. Cancer Res 73: 4098-4111, 2013.
298. Long H, Wang Z, Chen J, Xiang T, Li Q, Diao X and Zhu B: microRNA-214 promotes epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting the suppressorof-fused protein (Sufu). Oncotarget 6: 38705-38718, 2015.
299. Liu X, Chen Q, Yan J, Wang Y, Zhu C, Chen C, Zhao X, Xu M, Sun Q, Deng R, et al: MiRNA-296-3p-ICAM-1 axis promotes metastasis of prostate cancer by possible enhancing survival of natural killer cell-resistant circulating tumour cells. Cell Death Dis 4: e928, 2013.
300. Vaira V, Faversani A, Martin NM, Garlick DS, Ferrero S, Nosotti M, Kissil JL, Bosari S and Altieri DC: Regulation of lung cancer metastasis by Klf4-Numb-like signaling. Cancer Res 73: 2695-2705, 2013.
301. Ni F, Zhao H, Cui H, Wu Z, Chen L, Hu Z, Guo C, Liu Y, Chen Z, Wang X, et al: MicroRNA-362-5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma. Cancer Lett 356: 809-818, 2015.
302. Chen D, Dang BL, Huang JZ, Chen M, Wu D, Xu ML, Li R and Yan GR: MiR373 drives the epithelial-to-mesenchymal transition and metastasis via the miR373-TXNIP-HIF1-TWIST signaling axis in breast cancer. Oncotarget 6: 32701-32712, 2015.
303. Lu S, Zhu Q, Zhang Y, Song W, Wilson MJ and Liu P: Dual functions of miR373 and miR520c by differently regulating the activities of MMP2 and MMP9. J Cell Physiol 230: 1862-1870, 2015.
304. Glover AR, Zhao JT, Gill AJ, Weiss J, Mugridge N, Kim E, Feeney AL, Ip JC, Reid G, Clarke S, et al: MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget 6: 36675-36688, 2015.
305. Babae N, Bourajjaj M, Liu Y, Van Beijnum JR, Cerisoli F, Scaria PV, Verheul M, Van Berkel MP, Pieters EH, Van Haastert RJ, et al: Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. Oncotarget 5: 6687-6700, 2014.
306. Wang W, Dai LX, Zhang S, Yang Y, Yan N, Fan P, Dai L, Tian HW, Cheng L, Zhang XM, et al: Regulation of epidermal growth factor receptor signaling by plasmid-based microRNA-7 inhibits human malignant gliomas growth and metastasis in vivo. Neoplasma 60: 274-283, 2013.
307. Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, Komaki R, Giri DK, Quini CC, Wolfe T, et al: Therapeutic delivery of miR200c enhances radiosensitivity in lung cancer. Mol Ther 22: 1494-1503, 2014.
308. Wu X, Liu T, Fang O, Dong W, Zhang F, Leach L, Hu X and Luo Z: MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer. Oncotarget 7: 2417-2432, 2016.
309. Ge YF, Sun J, Jin CJ, Cao BQ, Jiang ZF and Shao JF: AntagomiR27a targets FOXO3a in glioblastoma and suppresses U87 cell growth in vitro and in vivo. Asian Pac J Cancer Prev 14: 963-968, 2013.
310. Shu M, Zheng X, Wu S, Lu H, Leng T, Zhu W, Zhou Y, Ou Y, Lin X, Lin Y, et al: Targeting oncogenic miR335 inhibits growth and invasion of malignant astrocytoma cells. Mol Cancer 10: 59, 2011.
311. Rather MI, Nagashri MN, Swamy SS, Gopinath KS and Kumar A: Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: Implications for cancer therapeutics. J Biol Chem 288: 608-618, 2013.
312. Haug BH, Henriksen JR, Buechner J, Geerts D, Tømte E, Kogner P, Martinsson T, Flægstad T, Sveinbjørnsson B and Einvik C: MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DiCKK OPF-3 (DKK 3) in neuroblastoma. Carcinogenesis 32: 1005-1012, 2011.
313. Tang H, Liu X, Wang Z, She X, Zeng X, Deng M, Liao Q, Guo X, Wang R, Li X, et al: Interaction of hsa-miR381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Res 1390: 21-32, 2011.
314. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW and Weinberg RA: Therapeutic silencing of miR10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 28: 341-347, 2010.
315. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, et al: The inhibition of the highly expressed miR221 and miR222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 3: e4029, 2008.
316. Zhao Y, Zhao L, Ischenko I, Bao Q, Schwarz B, Nieß H, Wang Y, Renner A, Mysliwietz J, Jauch KW, et al: Antisense inhibition of microRNA-21 and microRNA-221 in tumorinitiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer. Target Oncol 10: 535-548, 2015.
317. Wagenaar TR, Zabludoff S, Ahn SM, Allerson C, Arlt H, Baffa R, Cao H, Davis S, Garcia-Echeverria C, Gaur R, et al: Anti-miR21 suppresses hepatocellular carcinoma growth via broad transcriptional network deregulation. Mol Cancer Res 13: 1009-1021, 2015.
318. Fabani MM, Abreu-Goodger C, Williams D, Lyons PA, Torres AG, Smith KG, Enright AJ, Gait MJ and Vigorito E: Efficient inhibition of miR155 function in vivo by peptide nucleic acids. Nucleic Acids Res 38: 4466-4475, 2010.
319. Brognara E, Fabbri E, Aimi F, Manicardi A, Bianchi N, Finotti A, Breveglieri G, Borgatti M, Corradini R, Marchelli R, et al: Peptide nucleic acids targeting miR221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells. Int J Oncol 41: 2119-2127, 2012.
320. Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, Fu J, Zeng MS, Yun JP, Wu QL, et al: Knockdown of miR21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res 13: R2, 2011.
321. Zhang J and Ma L: MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev 31: 653-662, 2012.
322. Zaravinos A, Radojicic J, Lambrou GI, Volanis D, Delakas D, Stathopoulos EN and Spandidos DA: Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer. J Urol 188: 615-623, 2012.
323. Kiesslich T, Pichler M and Neureiter D: Epigenetic control of epithelial-mesenchymal-transition in human cancer. Mol Clin Oncol 1: 3-11, 2013.
324. Lei C, Wang Y, Huang Y, Yu H, Huang Y, Wu L and Huang L: Up-regulated miR155 reverses the epithelial-mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in human Caski cervical cancer cells. PLoS One 7: e52310, 2012.
325. Koutsaki M, Spandidos DA and Zaravinos A: Epithelialmesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR200 family: Prognostic value and prospective role in ovarian cancer therapeutics. Cancer Lett 351: 173-181, 2014.
326. Gao H, Teng C, Huang W, Peng J and Wang C: SOX2 promotes the epithelial to mesenchymal transition of esophageal squamous cells by modulating Slug expression through the activation of STAT3/HIF-signaling.
327. Lambertini E, Lolli A, Vezzali F, Penolazzi L, Gambari R and Piva R: Correlation between Slug transcription factor and miR221 in MDA-MB-231 breast cancer cells. BMC Cancer 12: 445, 2012.
328. Qiu G, Lin Y, Zhang H and Wu D: miR139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2. Biochem Biophys Res Commun 463: 315-321, 2015.
329. Bezzerri V, Borgatti M, Finotti A, Tamanini A, Gambari R and Cabrini G: Mapping the transcriptional machinery of the IL-8 gene in human bronchial epithelial cells. J Immunol 187: 6069-6081, 2011.
330. Raychaudhuri B and Vogelbaum MA: IL-8 is a mediator of NF-B induced invasion by gliomas. J Neurooncol 101: 227-235, 2011.
331. Xie TX, Xia Z, Zhang N, Gong W and Huang S: Constitutive NF-B activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. Oncol Rep 23: 725-732, 2010.
332. Sun S, Wang Q, Giang A, Cheng C, Soo C, Wang CY, Liau LM and Chiu R: Knockdown of CypA inhibits interleukin-8 (IL-8) and IL-8-mediated proliferation and tumor growth of glioblastoma cells through down-regulated NF-B. J Neurooncol 101: 1-14, 2011.
333. Gabellini C, Castellini L, Trisciuoglio D, Kracht M, Zupi G and Del Bufalo D: Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma. J Neurochem 107: 871-882, 2008.
334. Yang TQ, Lu XJ, Wu TF, Ding DD, Zhao ZH, Chen GL, Xie XS, Li B, Wei YX, Guo LC, et al: MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-B1/MMP9 signaling pathway. Cancer Sci 105: 265-271, 2014.
335. Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, Yee AJ, Ang LC, He C, Shan SW, et al: MicroRNA miR93 promotes tumor growth and angiogenesis by targeting integrin-8. Oncogene 30: 806-821, 2011.
336. Magge SN, Malik SZ, Royo NC, Chen HI, Yu L, Snyder EY, O'Rourke DM and Watson DJ: Role of monocyte chemoattractant protein-1 (MCP-1/CCL2) in migration of neural progenitor cells toward glial tumors. J Neurosci Res 87: 1547-1555, 2009.
337. Nazarenko I, Hede SM, He X, Hedrén A, Thompson J, Lindström MS and Nistér M: PDGF and PDGF receptors in glioma. Ups J Med Sci 117: 99-112, 2012.
338. Cai JJ, Qi ZX, Chen LC, Yao Y and Gong Y and Mao Y: miR124 suppresses the migration and invasion of glioma cells in vitro via Capn4. Oncol Rep 35: 284-290, 2015.
339. Cheng Y, Li Y, Nian Y, Liu D, Dai F and Zhang J: STAT3 is involved in miR124-mediated suppressive effects on esophageal cancer cells. BMC Cancer 15: 306, 2015.
340. Dong LL, Chen LM, Wang WM, Zhang LM: Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer. Diagn Pathol 10: 45, 2015.
341. Long QZ, Du YF, Liu XG, Li X and He DL: miR124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma. Tumour Biol 36: 7017-7026, 2015.
342. Lu SH, Jiang XJ, Xiao GL, Liu DY and Yuan XR: miR124a restoration inhibits glioma cell proliferation and invasion by suppressing IQGAP1 and-catenin. Oncol Rep 32: 2104-2110, 2014.
343. Chen SM, Chou WC, Hu LY, Hsiung CN, Chu HW, Huang YL, Hsu HM, Yu JC and Shen CY: The Effect of MicroRNA-124 overexpression on anti-tumor drug sensitivity. PLoS One 10: e0128472, 2015.
344. Fabbri E, Brognara E, Montagner G, Ghimenton C, Eccher A, Cantù C, Khalil S, Bezzerri V, Provezza L, Bianchi N, et al: Regulation of IL-8 gene expression in gliomas by microRNA miR93. BMC Cancer 15: 661, 2015.
345. Fabbri E, Montagner G, Bianchi N, Finotti A, Borgatti M, Lampronti I, Cabrini G and Gambari R: MicroRNA miR93-5p regulates expression of IL-8 and VEGF in neuroblastoma SK-N-AS cells. Oncol Rep 35: 2866-2872, 2016.
346. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA and Farace MG: miR221 and miR222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 282: 23716-23724, 2007.
347. Lu X, Zhao P, Zhang C, Fu Z, Chen Y, Lu A, Liu N, You Y, Pu P and Kang C: Analysis of miR221 and p27 expression in human gliomas. Mol Med Rep 2: 651-656, 2009.
348. Gillies JK and Lorimer IA: Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 6: 2005-2009, 2007.
349. Wang Y, Wang X, Zhang J, Sun G, Luo H, Kang C, Pu P, Jiang T, Liu N and You Y: MicroRNAs involved in the EGFR/PTEN/ AKT pathway in gliomas. J Neurooncol 106: 217-224, 2012.
350. Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze MT, et al: Dicerregulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci USA 106: 10746-10751, 2009.
351. Zhang J, Han L, Ge Y, Zhou X, Zhang A, Zhang C, Zhong Y, You Y, Pu P and Kang C: miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. Int J Oncol 36: 913-920, 2010.
352. Zhang C, Jiang T, Wang J, Cheng J, Pu P and Kang C: MiR221/222 promote the growth of malignant glioma cells by regulating its target genes, molecular targets of CNS tumors. Dr Miklos Garami (Ed). ISBN: 978-953-307-736-9. InTech, pp461-482, 2011.
353. Sarkar S, Dubaybo H, Ali S, Goncalves P, Kollepara SL, Sethi S, Philip PA and Li Y: Down-regulation of miR221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer Res 3: 465-477, 2013.
354. Zhang C, Kang C, You Y, Pu P, Yang W, Zhao P, Wang G, Zhang A, Jia Z, Han L, et al: Co-suppression of miR221/222 cluster suppresses human glioma cell growth by targeting p27Kip1 in vitro and in vivo. Int J Oncol 34: 1653-1660, 2009.
355. Zhang R, Pang B, Xin T, Guo H, Xing Y, Xu S, Feng B, Liu B and Pang Q: Plasma miR-221/222 family as novel descriptive and prognostic biomarkers for glioma. Mol Neurobiol 53: 1452-1460, 2016.
356. Yang Y, Li F, Saha MN, Abdi J, Qiu L and Chang H: miR137/197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma. Clin Cancer Res 21: 2399-2411, 2015.
357. Lee SH, Jung YD, Choi YS and Lee YM: Targeting of RUNX3 by miR130a and miR495 cooperatively increases cell proliferation and tumor angiogenesis in gastric cancer cells. Oncotarget 6: 33269-33278, 2015.
358. Brognara E, Fabbri E, Montagner G, Gasparello J, Manicardi A, Corradini R, Bianchi N, Finotti A, Breveglieri G, Borgatti M, et al: High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR221 and miR222. Int J Oncol 48: 1029-1038, 2016.
359. Giunti L, da Ros M, Vinci S, Gelmini S, Iorio AL, Buccoliero AM, Cardellicchio S, Castiglione F, Genitori L, de Martino M, et al: Anti-miR21 oligonucleotide enhances chemosensitivity of T98G cell line to doxorubicin by inducing apoptosis. Am J Cancer Res 5: 231-242, 2014.
360. Gao C, Peng FH and Peng LK: MiR200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1. Neoplasma 61: 680-689, 2014.
361. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI and Kovalchuk O: Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 127: 1785-1794, 2010.
362. Suto T, Yokobori T, Yajima R, Morita H, Fujii T, Yamaguchi S, Altan B, Tsutsumi S, Asao T and Kuwano H: MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis 36: 338-345, 2015.
363. Liu R, Liu X, Zheng Y, Gu J, Xiong S, Jiang P, Jiang X, Huang E, Yang Y, Ge D, et al: MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel. Oncol Lett 8: 2193-2200, 2014.
364. Gomes SE, Simões AE, Pereira DM, Castro RE, Rodrigues CM and Borralho PM: miR143 or miR145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells. Oncotarget: Jan 25, 2016 (Epub ahead of print).
365. Costa PM, Cardoso AL, Nóbrega C, Pereira de Almeida LF, Bruce JN, Canoll P and Pedroso de Lima MC: MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma. Hum Mol Genet 22: 904-918, 2013.
366. Qian X, Ren Y, Shi Z, Long L, Pu P, Sheng J, Yuan X and Kang C: Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR21 inhibitor gene therapy. Mol Pharm 9: 2636-2645, 2012.
367. Zhang S, Han L, Wei J, Shi Z, Pu P, Zhang J, Yuan X and Kang C: Combination treatment with doxorubicin and microRNA-21 inhibitor synergistically augments anticancer activity through upregulation of tumor suppressing genes. Int J Oncol 46: 1589-1600, 2015.
368. Zhang Q, Ran R, Zhang L, Liu Y, Mei L, Zhang Z, Gao H and He Q: Simultaneous delivery of therapeutic antagomirs with paclitaxel for the management of metastatic tumors by a pH-responsive anti-microbial peptide-mediated liposomal delivery system. J Control Release 197: 208-218, 2015.
369. Fan L, Yang Q, Tan J, Qiao Y, Wang Q, He J, Wu H and Zhang Y: Dual loading miR218 mimics and Temozolomide using AuCOOH@FA-CS drug delivery system: Promising targeted anti-tumor drug delivery system with sequential release functions. J Exp Clin Cancer Res 34: 106, 2015.
370. Xue W, Dahlman JE, Tammela T, Khan OF, Sood S, Dave A, Cai W, Chirino LM, Yang GR, Bronson R, et al: Small RNA combination therapy for lung cancer. Proc Natl Acad Sci USA 111: E3553-E3561, 2014.
371. Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, et al: Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov 3: 1302-1315, 2013.
372. Hu X, Li W, Liu G, Wu H, Gao Y, Chen S, He D and Zhang Y: The effect of Bcl-2 siRNA combined with miR15a oligonucleotides on the growth of Raji cells. Med Oncol 30: 430, 2013.